期刊名称：JOURNAL OF PHARMACEUTICAL SCIENCES
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
The Journal of Pharmaceutical Sciences will publish original research papers, original research notes, invited topical reviews (including Minireviews), and editorial commentary and news. The area of focus shall be concepts in basic pharmaceutical science and such topics as chemical processing of pharmaceuticals, including crystallization, lyophilization, chemical stability of drugs, pharmacokinetics, biopharmaceutics, pharmacodynamics, pro-drug developments, metabolic disposition of bioactive agents, dosage form design, protein-peptide chemistry and biotechnology specifically as these relate to pharmaceutical technology, and targeted drug delivery. |
|
Instructions to Authors
New: Online Submission and Peer Review
Taking a step toward expediting the publication process, the Journal of Pharmaceutical Sciences is now pleased to offer web-based submission and peer review. To submit your manuscript online, please:
1. Prepare your manuscript and illustrations in appropriate format, according to the instructions given at http://jpharmsci-wiley.manuscriptcentral.com/ under the "Instructions and Forms" button. Please also be sure that your paper conforms to the scientific and style instructions of the Journal, given below here.
2. If you have not already done so, create an account for yourself in the system at the submission site, http://jpharmsci-wiley.manuscriptcentral.com/ by clicking on the "Create an Account" button. To monitor the progress of your manuscript throughout the review process, just login periodically and check your Author Center.
3. Please be sure to study the Instructions and Forms given at the site carefully, and then let the system guide you through the submission process. Online help is available to you at all times during the process. You are also able to exit/re-enter at any stage before finally "submitting" your work. All submissions are kept strictly confidential. If you have any questions, do not hesitate to contact us at edsupport@wiley.com. You may also contact the Journal's Editorial Assistant, Tammy Dunning, at tdunning@ku.edu, or at tel. 785-864-5919, fax 785-864-5875.
2. Scope of the Journal of Pharmaceutical Sciences.
The Journal focuses on two major questions of importance to pharmaceutical scientists: (1) What are the physical and biological barriers that limit the access of drugs to their therapeutic targets?, and (2) How can drugs, dosage forms and delivery systems be designed to maximize therapeutic efficacy? Articles, Communications, Notes, Reviews, Minireviews and Commentaries that address these questions quantitatively and mechanistically will be considered for publication in the Journal. It is expected that these contributions will span a variety of disciplines, including physical pharmacy, pharmaceutical engineering, materials science, pharmacokinetics/ pharmacodynamics, pharmacogenomics, animal and human biopharmaceutics, cellular and molecular biopharmaceutics, drug delivery, drug metabolism, pharmaceutical biotechnology, analytical chemistry, computer modeling and medicinal chemistry. Specific scientific topics of interest to the Journal include, but are not limited to, preformulation and formulation studies, crystallization, polymorphism, drug stability, selection of salt forms and excipients, pharmaceutical process design and manufacturing, preclinical and clinical pharmacokinetics, cell and tissue culture models, transport in biological membranes and associated transport proteins, controlled release, drug targeting, oral and parenteral drug delivery, prodrugs, formulation and delivery of biomacromolecules (proteins, DNA) and vaccines, high throughput screening, novel analytical methods for drug characterization, and computational and modeling approaches to drug design, formulation and delivery.
All manuscripts are evaluated for their scientific content and significance by the Editor, an Associate Editor, a member of the Editorial Advisory Board and at least two independent reviewers.
3. Types of Manuscripts.
Articles are comprehensive accounts of significant experimental or theoretical results. While there are no fixed limitations to the length of an article, authors are asked to write their manuscripts in a clear and concise manner and to include only data crucial to arriving at their final conclusions.
Communications are preliminary reports limited to approximately 1,500 words (including tables, figures and references). They must be of sufficient importance and general interest to justify accelerated publication.
Notes differ from Communications in that they are final reports, and from Articles in that they are limited in scope. Notes must be of high quality, of general interest and of sufficient importance to warrant publication. They are limited to approximately 1,500 words (including tables, figures and references).
Commentaries present the author¡¯s considered opinion on a scientific or technical subject within the scope of the Journal. Commentaries are limited to 2,000 words. If the Commentary criticizes an article published in the Journal, the authors of the original article will be given an opportunity to reply in the same issue in which the Commentary is published.
Perspectives articles summarize the viewpoints of distinguished pharmaceutical scientists with regard to the current status and future direction of the field. Perspectives are similar in length to Commentaries, and may be submitted only by invitation.
Review Articles provide a comprehensive summary of broadly-based topics of general interest to pharmaceutical scientists. Reviews are not limited as to the number of words, tables, figures and references that may be included.
Minireviews are well-focused, well-documented examinations of timely issues in the pharmaceutical sciences. The issues may be of a controversial nature, or may address a more narrowly focused area than those typically covered in a Review. Minireviews are limited to approximately 3,000-4,000 words, including tables, figures and references.
Reviews and Minireviews are by invitation only. Authors interested in preparing a Commentary, Review Article, or Minireview should provide a brief outline to Associate Editor Elizabeth Topp, requesting an invitation to submit a manuscript in one of these categories.
4. Preparation of Manuscripts.
(a) General Considerations.
Authors are strongly encouraged to submit their manuscripts online to expedite peer review at http://jpharmsci-wiley.manuscriptcentral.com
If authors are unable to submit online, then five copies of the manuscript must be submitted together with a transmittal letter and a signed Copyright Transfer Agreement to the Editor, Dr. Ronald T. Borchardt, Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Room 121A, Lawrence, KS 66047. Tel: (785) 864-5919/7355; Fax: (785) 864-5875; E-mail: rborchardt@ku.edu Correspondence regarding accepted papers, proofs, and reprints should be directed to the Publisher, STM Division, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030.
For those authors not submitting online, it should be noted that the final accepted version of the manuscript should be in electronic format. For further information concerning electronic submission of final accepted manuscripts, a Disk Submission Instructions form is available immediately following these Instructions for Authors, or by request to alinefsk@wiley.com.
Manuscripts must be typed (or reproduced on a high-quality printer) double-spaced on 22 ¡Á 28 cm (or A4) paper on one side only. One copy must be a good, clear typescript, stencil, or photoduplicating machine product. The original manuscript should include the original inked drawings or photographs of structural formulas for direct use. High-quality output from laser printers is acceptable. General information on the preparation of manuscripts may be found in The ACS Style Guide, 2nd ed. (1997). Authors should write in clear, concise English. The responsibility for all aspects of manuscript preparation rests with the authors. Extensive changes or rewriting of the manuscript will not be undertaken by the editors.
(b) Suggested Reviewers. The Journal requires that submitting authors suggest at least two reviewers, up to a maximum of four reviewers. Please include suggested reviewers' contact information.
(c) Assembly. Authors submitting their manuscripts online need only follow the instructions provided at http://jpharmsci-wiley.manuscriptcentral.com. For those who are unable to submit online, please note that separate sheets should be used for the title page, with authors' names and affiliations, and for the abstract. References and notes, tables, and figure legends should be grouped on separate sheets, in that order. Every page, beginning with the title page, should be numbered. Be consistent in author designation and supply given name, initial of second name, and last name. Give the complete mailing address of the place where the work was done and include the telephone, fax number, and e-mail address of the corresponding author. Add the current address and e-mail of each author, if different, on the title page of the manuscript with a numerical superscript and footnote. The corresponding author is indicated by a superscript * (e.g., Smith* ).
(d) Title. Titles are of great importance for current awareness and for information retrieval. The wording of titles should be chosen carefully to provide information on the contents and to function as "points of entry" for information retrieval. Symbols, formulas, or arbitrary abbreviations should not be included in the title, except chemical symbols to indicate the structure of isotopically labeled compounds.
(e) Abstract. The abstract should briefly (80-200 words) present, in one paragraph, the problem and experimental approach and state the major findings and conclusions. It should be self-explanatory and suitable for reproduction without rewriting. Footnotes or undefined abbreviations may not be used. If a reference must be cited, complete publication data must be given.
(f) Keywords. Please provide up to 10 keywords that reflect the scientific content of your manuscript. At least 5 of your selected keywords must come from the Journal's official keyword list, attached. In addition to facilitating indexing of articles, our keyword system assists in the assignment of qualified reviewers for your manuscript.
Official Keyword List (.pdf)
Notice: Articles accepted for publication in the Journal of Pharmaceutical Sciences will be posted in the Online edition of the journal (http://www.interscience.wiley.com) as soon as author corrections to proofs are received and incorporated. This can occur anywhere from 2 to 6 weeks in advance of the cover date of the printed issue. Authors should take this into account when planning their intellectual and patent activities related to an article. The actual date on which the article is posted online is recorded in a separate line at the bottom of the first page of the article in the printed issue.
(g) Abbreviations. Abbreviations are used without periods. Standard abbreviations should be used throughout the manuscript. All nonstandard abbreviations should be kept to a minimum and must be defined in the text following their first use.
(h) QSAR/QSPR. All manuscripts dealing with quantitative structure activity relationships (QSAR) and quantitative structure property relationships (QSPR) must identify individual chemical structures using Chemical Abstracts Service (CAS) SciFinder. To aid authors in the use of CAS SciFinder for structure searching, please click here for a Commentary written by Dr. Christopher Lipinski describing the procedure. This Commentary appears in Journal of Pharmaceutical Sciences 91(12): 2470-2472.
(i) Experimental Section. The experimental procedures should be described in sufficient detail to enable others to repeat the experiments. Names of products and manufacturers [with city, state, and country (if other than the U.S.)] should be included only if alternate sources are deemed unsatisfactory. Brand names may be used only once in the manuscript. For subsequent designation, use "formulation A", product B", etc. Novel experimental procedures should be described in detail, but published procedures should merely be referred to by literature citation of both the original and any published modifications. The purity of key compounds and descriptions(s) of the method(s) used to determine purity should be included in this section. For buffers, use terminology such as "20 mM potassium phosphate buffer (pH 7.7) containing...". Also, state w/v or v/v when appropriate.
Identification of and precautions for handling hazardous chemicals and dangerous procedures should be placed at the beginning of the section. An example would be "Caution: The following chemicals are hazardous and should be handled carefully; (list of chemicals and handling procedures or references)".
(j) Results. The results should be presented concisely. Tables and figures should be designed to maximize the presentation and comprehension of the experimental data. Attention should be paid to the matter of significant figures (usually, no more than three). The same data should not be presented in more than one figure or in both a figure and a table. As a rule, interpretation of the results should be reserved for the discussion section of an Article, but under some circumstances it may be desirable to combine results and discussion in a single section.
(k) Discussion.The purpose of the discussion is to interpret the results and to relate them to existing knowledge in the field in as clear and brief a fashion as possible. Information given elsewhere in the manuscript should not be repeated in the discussion. Extensive reviews of the literature should be avoided.
(l) References and Notes.
Wiley's Journal Styles Are Now in EndNote
EndNote is a software product that we recommend to our journal authors to help simplify and streamline the research process. Using EndNote's bibliographic management tools, you can search bibliographic databases, build and organize your reference collection, and then instantly output your bibliography in any Wiley journal style.
Download Reference Style for this Journal: If you already use EndNote, you can download the reference style for this journal.
How to Order: To learn more about EndNote, or to purchase your own copy, click here.
Technical Support: If you need assistance using EndNote, contact endnote@isiresearchsoft.com, or visit www.endnote.com/support.
Literature references and notes must be numbered in one consecutive series by order of mention in the text, with numbers as unparenthesized superscripts. The accuracy of the references is the responsibility of the author. The complete list of references and notes should be typed double-spaced on separate page(s) at the end of the manuscript and follow the format shown. All references should include titles. For journals: Yoneto K, Li SK, Higuchi WI, Jiskoot W, Herron JN 1996. Fluorescence probe studies of the interactions of 1-alkyl-2-pyrrolidones with stratum corneum lipid liposomes. J Pharm Sci 85:511-517. For edited books: Rall TW, Schleifer LS. 1985. Drugs effective in the therapy of the epilepsies. In Gilman AG, Goodman LS, Rall TW, Murad F, editors. The pharmacological basis of therapeutics, 7th ed., New York: Macmillan Publishing Co. p 446-472. List submitted manuscripts as "in press" only if formally accepted for publication; otherwise, use "unpublished results" after the names of authors. Any footnotes to the text should be incorporated in the correct numerical sequence with the references.
(m) Supporting Information. The Supporting Information format of this journal can accommodate and make readily available almost any type of supplementary figures or data (e.g., reproductions of spectra, experimental procedures, tabulated data, expanded discussion of peripheral findings, etc.). The author should include a Supporting Information Available statement that describes the material at the end of the printed manuscript text. Consult a current issue of the Journal for the proper wording of this statement. Supporting Information should be clear and of high contrast (suitable for direct photoreproduction) and submitted in quadruplicate on 8.5- ¡Á 11-in. paper. All pages of Supporting Information must be consecutively numbered. Captions or legends for figures, spectra, etc., must appear directly on the figure. Supporting Information is available free of charge via the Internet (http://www.interscience.wiley.com/).
(n) Acknowledgments. This section should acknowledge financial support, technical assistance, advice from colleagues, gifts, etc. Permission must be received from persons whose contribution to the work is acknowledged in the manuscript.
(o) Spectral Data. It may be desirable to include such data for representative compounds in a series, for novel classes of compounds, and in structural determinations. Usually, it is not desirable to include routine spectral data for every compound in the manuscript. Papers where interpretations of spectra are critical to structural elucidation and those in which band shape or fine structure needs to be illustrated may be published with spectra included. When such presentations are deemed essential, only pertinent sections should be reproduced.
(p) Biological Data. Biological test methods must be referenced or described in sufficient detail to permit the experiments to be repeated by others. Detailed descriptions of biological methods should be placed in the experimental procedures section. Data may be presented as numerical expressions or in graphical form. Statistical limits (statistical significance) for the biological data are usually required. If statistical limits cannot be provided, the number of determinations and some indication of the variability and reliability of the results should be given. References to statistical methods of calculation should be included. Doses and concentrations should be expressed as molar quantities (e.g., mmol/kg, mM) when comparisons of potencies are made on compounds having large differences in molecular weights. The routes of administration of test compounds and vehicles used should be indicated.
(q) Tables. Tabulation of experimental results is encouraged when this leads to more effective presentation or to more economical use of space. Tables should be numbered consecutively with Arabic numerals. Provide a brief title with each table and a brief heading for each column. Clearly indicate the units of measure (preferably SI). Data should be rounded to the nearest significant figure. Explanatory material referring to the whole table is to be included as a footnote to the title (a). Footnotes in tables should be given lower case letter designations and cited in the tables as italicized superscripts. Tables that require special treatment, such as insertion of arrows or other special symbols under or over alphanumeric characters, or contain many structures should be submitted as camera-ready copy. All tables should be cited in the text.
(r) Illustrations. The quality of the illustrations printed in your paper depends on the quality of the originals you provide. Electronic submission of illustrations is encouraged. Preferred formats for graphics and artwork include, but are not limited to, TIFF (tagged image file format), JPEG and EPS (Encapsulated PostScript). John Wiley & Sons, Inc. journal pages are now produced completely electronically. If not submitted electronically, the chemical structures, graphs, photographs, or other illustrations you send with your paper will be scanned into the journal page using a digital scanner. The scanner is very sensitive; it will faithfully copy all flaws such as smudges, uneven lines, incomplete erasures, etc.
In preparing illustrations, contrast is important. Use dark black ink on high quality, smooth, opaque white paper. Ordinary white bond paper works well. Avoid tracing paper or textured "artist" papers.
Illustrations must fit a one- or two-column format on the journal page: For efficient use of journal space, single column illustrations are preferred.
|
Single (preferred) |
Double |
|
Minimum Width |
|
9 cm (3.5 in) |
|
Maximum Width |
8 cm (3.125 in) |
16.5 cm (6.5 in) |
|
Maximum Depth |
23 cm (9 in) |
23 cm (9 in) |
For best results, submit illustrations in the actual size at which they should appear in the journal. Original illustrations which do not need to be reduced to fit a single or double column will yield the best quality. Lettering should be no smaller than 4.5 points. (Helvetica type works well for lettering.) Lines should be no thinner than 0.5 point. Lettering and lines should be of uniform density. If you must submit artwork that must be reduced, use larger lettering and thicker lines so that, when reduced, the artwork meets the above-mentioned parameters. Avoid using complex textures and shading to achieve a three-dimensional effect. To show a pattern, choose a simple cross-hatch design.
Submit only original artwork or high quality photographic prints of originals; photocopies do not reproduce well. Artwork produced by a high-quality graphics plotter will yield a better printed result than artwork produced on a dot-matrix, laser, or inkjet printer. If your material must be prepared on one of these printers, use high-quality laser paper and choose the highest resolution available. For example, select 600 dpi rather than 300 dpi.
Photographs. High-contrast prints with a smooth or glossy finish work best. Send photographs that are single or double column width so that they will not have to be reduced. Do not submit negatives, slides, or vugraphs. Avoid photographs produced on a laser printer and prints cut from a printed publication; these do not give good results. Do not write on the front or back of the image area of the photograph. These marks may show through when the photograph is scanned.
Color. All color figures will be reproduced in full color in the online edition of the journal at no cost to the authors. Authors are required to pay the cost of reproducing color figures in print. Authors are encouraged to submit color illustrations that highlight the text and convey essential scientific information. For best reproduction, bright, clear colors should be used. Dark colors against a dark background do not reproduce well; please place your color images against a white background whenever possible. Please contact Alyson Linefsky at 201-748-6723 (phone)/alinefsk@wiley.com (email) for further information.
Chemical Structures. Structures should be produced with the use of a drawing program such as ChemDraw. Authors using the current versions of ChemDraw, ChemIntosh, and ChemWindows will find the necessary parameters incorporated into these programs ("JOC Document" under the Windows menus for ChemDraw and "Reduce 60% for JOC Style" under the Options menu for ChemIntosh/ChemWindows). In ChemDraw version 4.5, files should be saved in TIFF format to allow use of electronic files in production (see journal home page "Information for Authors" for further guidelines).
(s) Nomenclature. It is the responsibility of the authors to provide correct nomenclature. All nomenclature must be consistent and unambiguous and should conform with current American usage. Insofar as possible, authors should use systematic names similar to those used by Chemical Abstracts Service, the International Union of Pure and Applied Chemistry, and the International Union of Biochemistry and Molecular Biology.
The chemical names for drugs should be used. If the terminology is unwieldy, nonproprietary names of drugs may be used throughout the manuscript after the first mention and identification. Formally adopted nonproprietary names listed in United States Adopted Names(USAN) should be used. In cases in which a name has not been assigned by USAN, the International Nonproprietary Names (INN), approved by the World Health Organization, should be used. Trade names and laboratory codes should not be used except as additional information.
(t) Analyses. Adequate evidence to establish identity and purity should be provided for new compounds. When possible, this should include elemental analysis. The purity of compounds used for biological testing should be stated with a description of the method used to evaluate it.
(u) Hazardous Materials. All hazardous chemicals should be clearly identified as such. Precautions for handling dangerous materials or for performing hazardous procedures should be explicitly stated and referenced.
5. Proofs and Reprints. Proofs are sent to the author who submitted the papers. Authors are directed via email to download proofs from a secure FTP site unless authors request otherwise. Proofs should be verified against the manuscript and appropriate corrections made. Substantial changes in a manuscript after type has been set require editorial approval and in some cases may be cause for re-reviewing. An order form for reprints will be sent with the proofs. Please return the reprint order form, along with a purchase order or check, to John Wiley & Sons, Inc. Reprints will be shipped within 2 weeks after the printed journal date.
6. Corrections. If errors of consequence are found in the published paper, a correction of the error should be sent by the author to the Editor for publication in the corrections and Additions section.
7. There are no page charges for the Journal of Pharmaceutical Sciences.
8. Copyright Transfer Agreements must accompany manuscripts when they are initially submitted. You may photocopy the form, which can usually be found in each year's January issue of the Journal, or download the form from the online Journal Information button at http://www.interscience.wiley.com/
Disk Submission Instructions
Please return your final, revised manuscript on disk as well as hard copy.
The hard copy must match the disk.
The Journal strongly encourages authors to deliver the final, revised version of their accepted manuscripts (text, tables, and, if possible, illustrations) on disk. Given the near-universal use of computer word-processing for manuscript preparation, we anticipate that providing a disk will be convenient for you, and it carries the added advantages of maintaining the integrity of your keystrokes and expediting typesetting. Please return the disk submission slip below with your manuscript and labeled disk(s).
Guidelines for Electronic Submission
Text
Storage medium. 3-1/2" high-density disk in IBM MS-DOS, Windows, or Macintosh format.
Software and format. Microsoft Word 2000 is preferred, although manuscripts prepared with any other microcomputer word processor are acceptable. Refrain from complex formatting; the Publisher will style your manuscript according to the Journal design specifications. Do not use desktop publishing software such as Aldus PageMaker or Quark XPress. If you prepared your manuscript with one of these programs, export the text to a word processing format. Please make sure your word processing program's "fast save" feature is turned off. Please do not deliver files that contain hidden text: for example, do not use your word processor's automated features to create footnotes or reference lists.
File names. Submit the text and tables of each manuscript as a single file. Name each file with your last name (up to eight letters). Text files should be given the three-letter extension that identifies the file format. Macintosh users should maintain the MS-DOS "eight dot three" file-naming convention.
Labels. Label all disks with your name, the file name, and the word processing program and version used.
Illustrations
All print reproduction requires files for full color images to be in a CMYK color space. If possible, ICC or ColorSync profiles of your output device should accompany all digital image submissions.
Storage medium. Submit as separate files from text files, on separate disks or cartridges. If feasible, full color files should be submitted on separate disks from other image files. 3-1/2" high-density disks, CD, Iomega Zip, and 5 1/4" 44- or 88-MB SyQuest cartridges can be submitted. At authors' request, cartridges and disks will be returned after publication.
Software and format. All illustration files should be in TIFF or EPS (with preview) formats. Do not submit native application formats.
Resolution. Journal quality reproduction will require greyscale and color files at resolutions yielding approximately 300 ppi. Bitmapped line art should be submitted at resolutions yielding 600-1200 ppi. These resolutions refer to the output size of the file; if you anticipate that your images will be enlarged or reduced, resolutions should be adjusted accordingly.
File names. Illustration files should be given the 2- or 3-letter extension that identifies the file format used (i.e., .tif, .eps).
Labels. Label all disks and cartridges with your name, the file names, formats, and compression schemes (if any) used. Hard copy output must accompany all files.
Editorial Board
EDITOR
Dr. Ronald T. Borchardt
Department of Pharmaceutical Chemistry
The University of Kansas
2095 Constant Ave., Room 121a
Lawrence, Kansas 66047
E-mail: rborchardt@ku.edu
ASSOCIATE EDITORS
Bradley D. Anderson
University of Kentucky
Lexington, KY
E-mail: bande2@uky.edu
David J. W. Grant
University of Minnesota
Minneapolis, MN
E-mail: grant001@umn.edu
Richard Guy
University of Geneva
Geneva, Switzerland
E-mail: richard.guy@pharm.unige.ch
C. Russell Middaugh
University of Kansas
Lawrence, KS
E-mail: middaugh@ku.edu
Gary Pollack
University of North Carolina
Chapel Hill, NC
E-mail: gary_pollack@unc.edu
Akira Tsuji
Kanazawa University
Kanazawa, Ishikawa, Japan
E-mail: tsuji@kenroku.kanazawa-u.ac.jp
ASSOCIATE EDITOR OF REVIEWS, MINIREVIEWS, AND COMMENTARIES
Elizabeth M. Topp
University of Kansas
Lawrence, KS
E-mail: topp@ku.edu
EDITORIAL ADVISORY BOARD
Sandra R.B. Allerheiligen
Eli Lilly and Company
Indianapolis, IN
E-mail: srba@lilly.com
Gregory E. Amidon
Pharmacia & Upjohn, Inc.
Kalamazoo, MI
E-mail: gregory.e.amidon@pharmacia.com
Thomas J. Anchordoquy
University of Colorado
Health Sciences Center
Denver, CO
E-mail: tom.anchordoquy@uchsc.edu
Per Artursson
Uppsala University
Uppsala, Sweden
E-mail: per.artursson@galenik.uu.se
Kenneth L. Audus
The University of Kansas
Lawrence, KS
E-mail: audus@ku.edu
Bruce J. Aungst
Absorption Systems
Exton, PA
E-mail: aungst@absorption.com
Gerrit Borchard
LACDR, Leiden University
Leiden, The Netherlands
E-mail: borchard@lacdr.leidenuniv.nl
J.A. Bouwstra
LACDR, Leiden University
Leiden, The Netherlands
E-mail: bouwstra@chem.leidenuniv.nl
David N. Brems
Amgen, Inc.
Thousand Oaks, CA
E-mail: dbrems@amgen.com
Harry G. Brittain
Center for Pharmaceutical Physics
Milford, NJ
E-mail: hbrittain@earthlink.net
Kenneth R. Brouwer
GlaxoSmithKline
Research Triangle Park, NC
E-mail: krb0229@gsk.com
Kim L.R. Brouwer
University of North Carolina
Chapel Hill, NC
E-mail: kbrouwer@unc.edu
Annette L. Bunge
Colorado School of Mines
Golden, CO
E-mail: abunge@mines.edu
Philip S. Burton
Pharmacia Corporation
Kalamazoo, MI
E-mail: philip.s.burton@pharmacia.com
Stephen R. Byrn
Purdue University
West Lafayette, IN
E-mail: sbyrn@sparky.pharmacy.purdue.edu
John F. Carpenter
University of Colorado Health
Sciences Center
Denver, CO
E-mail: john.carpenter@uchsc.edu
William N. Charman
Monash University
Parkville, Australia
E-mail: bill.charman@vcp.monash.edu.au
Jeffrey L. Cleland
Targesome, Inc.
Palo Alto, CA
E-mail: cleland@gene.com
Henry R. Costantino
Alkermes, Inc.
Cambridge, MA
E-mail: rick.costantino@alkermes.com
William Couet
University of Poitiers
Poitiers, France
E-mail: william.couet@univ-poitiers.fr
Duncan Q.M Craig
The Queen's University of Belfast
Belfast, UK
E-mail: duncan.craig@qub.ac.uk
John H. Crowe
University of California, Davis
Davis, CA
E-mail: jhcrowe@ucdavis.edu
Richard T. Darrington
Pfizer, Inc.
Groton, CT
E-mail: todd_darrington@groton.pfizer.com
Antony D'Emanuele
University of Manchester
Manchester, UK
E-mail: antony@demanuele.net
Jennifer Dressman
Johann Wolfgang von Goethe University
Frankfurt, Germany
E-mail: dressman@em.uni-frankfurt.de
Ruth Duncan
Cardiff University
Cardiff, UK
E-mail: duncanr@cf.ac.uk
William F. Elmquist
University of Nebraska
Medical Center
Omaha, NE
E-mail: wfelmqui@unmc.edu
Elias Fattal
University of Paris-Sud
Châtenay-Malabry, France
E-mail: elias.fattal@cep.u-psud.fr
Colin R. Gardner
TransForm Pharmaceuticals, Inc.
Waltham, MA
E-mail: gardner@transformpharma.com
Ferdinando Giordano
University of Parma
Parma, Italy
E-mail: ferdinando.giordano@unipr.it
Pamela L. Golden
Bristol-Myers Squibb
Wilmington, DE
E-mail: pam.golden@bms.com
Igor Gonda
Acrux Limited
Melbourne, Australia
E-mail: gondai@aradigm.com
Junichi Goto
Tohoku University
Aobayama, Sendai, Japan
E-mail: jun-goto@mail.pharm.tohoku.ac.jp
G. Richard Granneman
Abbott Laboratories
Abbott Park, IL
E-mail: rick.g.granneman@abbott.com
Suneel K. Gupta
ALZA Corporation
Mountain View, CA
E-mail: suneel.gupta@alza.com
Jonathan Hadgraft
University of Greenwich
Kent, UK
E-mail: jonathan.hadgraft@btinternet.com
Michael J. Hageman
Pharmacia Corporation
Kalamazoo, MI
E-mail: michael.j.hageman@pharmacia.com
Mitsuru Hashida
Kyoto University
Kyoto, Japan
E-mail: hashidam@pharm.kyoto-u.ac.jp
Masahiro Hayashi
Tokyo University of Pharmacy & Life Science
Tokyo, Japan
E-mail: hayashi@ps.toyaku.ac.jp
James N. Herron
University of Utah
Salt Lake City, UT
E-mail: herron@bioiris.pharm.utah.edu
Robert C. Hider
King's College
London, UK
E-mail: robert.hider@kcl.ac.uk
Rodney J.Y. Ho
University of Washington
Seattle, WA
E-mail: rodneyho@u.washington.edu
Toshio Honda
Hoshi University
Tokyo, Japan
E-mail: honda@hoshi.ac.jp
Lisbeth Illum
IDentity
Nottingham, UK
E-mail: lisbeth.illum@ccinternet.co.uk
Toshikiro Kimura
Okayama University
Okayama, Japan
E-mail: kimura@pheasant.pharm.okayama-u.ac.jp
Gregory T. Knipp
Rutgers University
Piscataway, NJ
E-mail: gknipp@cop.rutgers.edu
William J. Lambert
Eisai, Inc.
Research Triangle Park, NC
E-mail: bill_lambert@eisai.com
Robert S. Langer
Massachusetts Institute of Technology
Cambridge, MA
E-mail: rlanger@mit.edu
David Lechuga-Ballesteros
Inhale Therapeutic Systems
San Carlos, CA
E-mail: dlechuga@inhale.com
Christopher A. Lipinski
Pfizer Global Research & Development
Groton, CT
E-mail: christopher_a_lipinski@groton.pfizer.com
|
Michael B. Maurin
QS Pharma
Boothwyn, PA
E-mail: michael.maurin@qspharma.com
Patrick McNamara
University of Kentucky
Lexington, KY
E-mail: pmcnamar@uky.edu
Hans P. Merkle
ETH Zurich
Zurich, Switzerland
E-mail: hmerkle@pharma.anbi.ethz.ch
Kenneth R. Morris
Purdue University
West Lafayette, IN
E-mail: morris@pharmacy.purdue.edu
Marilyn E. Morris
State University of New York at Buffalo
Buffalo, NY
E-mail: memorris@acsu.buffalo.edu
Eric Munson
The University of Kansas
Lawrence, KS
E-mail: munson@ku.edu
Katsuhiko Okumura
Kobe University Hospital
Kobe, Japan
E-mail: okumorak@kobe-u.ac.jp
John S. Patton
Inhale Therapeutic Systems
San Carlos, CA
E-mail: patton@inhale.com
Michael J. Pikal
University of Connecticut
Storrs, CT
E-mail: pikal@uconnvm.uconn.edu
Véronique Préat
Universit?Catholique de Louvain
Brussels, Belgium
E-mail: preat@farg.ucl.ac.be
Theodore W. Randolph
University of Colorado
Boulder, CO
E-mail: randolph@pressure.colorado.edu
Thomas J. Raub
Pharmacia Corporation
Kalamazoo, MI
E-mail: thomas.j.raub@pharmacia.com
Kevin G. Rice
University of Iowa
Iowa City, IA
E-mail: kevin-rice@uiowa.edu
Naír Rodríguez-Hornedo
The University of Michigan
Ann Arbor, MI
E-mail: nrh@umich.edu
Mark C. Rogge
ZymoGenetics
Seattle, WA
E-mail: roggem@zgi.com
Chandra G. Sahajwalla
U.S. Food & Drug Administration
Gaithersburg, MD
E-mail: sahajwallac@cder.fda.gov
Ronald J. Sawchuk
University of Minnesota
Minneapolis, MN
E-mail: sawch001@maroon.tc.umn.edu
Christian Schöneich
The University of Kansas
Lawrence, KS
E-mail: schoneic@ukans.edu
Richard L. Schowen
The University of Kansas
Lawrence, KS
E-mail: rschowen@ku.edu
Steven P. Schwendeman
The University of Michigan
Ann Arbor, MI
E-mail: schwende@umich.edu
Kevin Shakesheff
University of Nottingham
Nottingham, UK
E-mail: kevin.shakesheff@nottingham.ac.uk
Ravi M. Shanker
Pfizer, Inc.
Groton, CT
E-mail: shankerrm@groton.pfizer.com
Danny D. Shen
University of Washington
Seattle, WA
E-mail: ds@u.washington.edu
Steven J. Shire
Genentech, Inc.
South San Francisco, CA
E-mail: shire.steve@gene.com
Ronald A. Siegel
University of Minnesota
Minneapolis, MN
E-mail: siege017@tc.umn.edu
Jeffrey A. Silverman
Sunesis Pharmaceuticals, Inc.
South San Francisco, CA
E-mail: jsilverman@sunesis.com
John T. Slattery
University of Washington
Seattle, WA
E-mail: jts@u.washington.edu
Janet G. Smith
Valentis Inc.
Burlingame, CA
E-mail: jkoe@valentis.com
Valentino J. Stella
The University of Kansas
Lawrence, KS
E-mail: stella@ukans.edu
Yuichi Sugiyama
The University of Tokyo
Tokyo, Japan
E-mail: sugiyama@mol.f.u-tokyo.ac.jp
Raj G. Suryanarayanan
University of Minnesota
Minneapolis, MN
E-mail: surya001@umn.edu
Peter W. Swaan
The Ohio State University
Columbus, OH
E-mail: swaan.1@osu.edu
Yun K. Tam
Kinetana Group Inc.
Edmonton, Alberta, Canada
E-mail: ytam@kinetana.com
Ikumi Tamai
Tokyo University of Science
Tokyo, Japan
E-mail: tamai@ps.kagu.sut.ac.jp
Lynne S. Taylor
Purdue University
West Lafayette, IN
E-mail: lynne.taylor@astrazeneca.com
Tetsuya Terasaki
Tohoku University
Sendai, Japan
E-mail: terasaki@mail.pharm.tohoku.ac.jp
Dhiren R. Thakker
The University of North Carolina
Chapel Hill, NC
E-mail: dhiren_thakker@unc.edu
Jashvant Unadkat
University of Washington
Seattle, WA
E-mail: jash@u.washington.edu
Michel Vert
CNRS-University Montpellier 1
Montpellier, France
E-mail: vertm@pharma.univ-montpl.fr
David B. Volkin
Centocor, Inc.
Malvern, PA
E-mail: dvolkin@cntus.jnj.com
Dominic J. Wells
Imperial College of Medicine
London, United Kingdom
E-mail: d.wells@ic.ac.uk
Timothy Wiedmann
University of Minnesota
Minneapolis, MN
E-mail: wiedm001@umn.edu
Jim Wright
Alkermes
Cambridge, MA
E-mail: jim.wright@alkermes.com
Akira Yamamoto
Kyoto Pharmaceutical University
Kyoto, Japan
E-mail: yamamoto@mb.kyoto-phu.ac.jp
Keiji Yamamoto
Chiba University
Chiba, Japan
E-mail: yamamotk@p.chiba-u.ac.jp
Sumie Yoshioka
National Institute of Health Sciences
Tokyo, Japan
E-mail: yoshioka@nihs.go.jp
Lian Yu
Eli Lilly and Company
Indianapolis, IN
E-mail: yu_lian@lilly.com
Hiroaki Yuasa
Nagoya City University
Nagoya, Japan
E-mail: yuasa@phar.nagoya-cu.ac.jp
Gaylen M. Zentner
Myriad Pharmaceuticals, Inc.
Salt Lake City, UT
E-mail: gzentner@myriad.com
Cheryl L. Zimmerman
University of Minnesota
Minneapolis, MN
George Zografi
University of Wisconsin
Madison, WI
E-mail: gzografi@facstaff.wisc.edu
| |
|
